ANL
NASDAQAdlai Nortye Ltd.
News25/Ratings8
News · 26 weeks45-22%
2026-04-192026-10-11
Mix2590d
- SEC Filings11(44%)
- Other7(28%)
- Insider4(16%)
- Leadership2(8%)
- Analyst1(4%)
Latest news
25 items- SECSEC Form 6-K filed by Adlai Nortye Ltd.6-K - Adlai Nortye Group Ltd. (0001944552) (Filer)
- PRAdlai Nortye Enters into Clinical Collaboration with Lilly and Merck KGaA, Darmstadt, Germany to Evaluate Combination of AN4035 and CetuximabAN4035, a first-in-class investigational pan-RAS(ON) inhibitor-based ADC, will be evaluated as monotherapy and in combination with cetuximab in the ongoing global Phase I trial Cetuximab will be supplied by Lilly for the U.S. trial sites Cetuximab will be supplied by Merck KGaA, Darmstadt, Germany for the Australia and China trial sites SINGAPORE and NORTH BRUNSWICK, N.J., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Adlai Nortye Group Ltd. (NASDAQ:ANL) ("Adlai Nortye" or the "Company"), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced clinical trial collaboration and supply agreements (CTCSAs) with Eli Lilly and Company ("Lilly") an
- INSIDERDirector Ji Ping sold $163,275 worth of American Depository shares (10,214 units at $15.99), decreasing direct ownership by 8% to 121,453 units (SEC Form 4)4 - Adlai Nortye Group Ltd. (0001944552) (Issuer)
- SECSEC Form 6-K filed by Adlai Nortye Ltd.6-K - Adlai Nortye Group Ltd. (0001944552) (Filer)
- PRAdlai Nortye Appoints Christopher Liu, PharmD, as Head of Investor Relations and Public RelationsSINGAPORE and NORTH BRUNSWICK, N.J., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Adlai Nortye Group Ltd. (NASDAQ:ANL) ("Adlai Nortye" or the "Company"), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced the appointment of Christopher Liu, PharmD, as Head of Investor Relations and Public Relations. Dr. Liu brings nearly a decade of equity research experience, with a focus on biotechnology and oncology. "We are pleased to welcome Chris to Adlai Nortye," said Carsten Lu, Chairman and Chief Executive Officer of Adlai Nortye. "His deep understanding of oncology and extensive experience in the healthcare capital markets will be valuable as
- SECSEC Form 6-K filed by Adlai Nortye Ltd.6-K - Adlai Nortye Group Ltd. (0001944552) (Filer)
- INSIDERDirector Ji Ping sold $83,150 worth of American Depository shares (5,000 units at $16.63), decreasing direct ownership by 4% to 131,667 units (SEC Form 4)4 - Adlai Nortye Group Ltd. (0001944552) (Issuer)
- SECSEC Form EFFECT filed by Adlai Nortye Ltd.EFFECT - Adlai Nortye Group Ltd. (0001944552) (Filer)
- SECSEC Form S-8 POS filed by Adlai Nortye Ltd.S-8 POS - Adlai Nortye Group Ltd. (0001944552) (Filer)
- SECSEC Form S-8 POS filed by Adlai Nortye Ltd.S-8 POS - Adlai Nortye Group Ltd. (0001944552) (Filer)
- SECSEC Form POS AM filed by Adlai Nortye Ltd.POS AM - Adlai Nortye Group Ltd. (0001944552) (Filer)
- ANALYSTJefferies initiated coverage on Adlai Nortye Ltd. with a new price targetJefferies initiated coverage of Adlai Nortye Ltd. with a rating of Buy and set a new price target of $31.00
- SECSEC Form 6-K filed by Adlai Nortye Ltd.6-K - Adlai Nortye Group Ltd. (0001944552) (Filer)
- PRAdlai Nortye Announces First Patient Dosed in Australia and U.S. FDA IND Clearance for AN4035, a First-in-Class Pan-RAS(ON) Inhibitor-Based ADCFirst-in-class CEACAM5-targeting ADC armed with a pan-RAS(ON) inhibitor – designed for tumor-selective RAS pathway inhibition First patient dosed in Australia; global Phase I initiated U.S. FDA cleared IND with "Study-May-Proceed" letter SINGAPORE and NORTH BRUNSWICK, N.J., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Adlai Nortye Group Ltd. (NASDAQ:ANL) ("Adlai Nortye" or the "Company"), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced that the first patient has been dosed with AN4035 in Australia, initiating the global Phase I trial in patients with CEACAM5-enriched RAS-addicted solid tumors. The Company also received a "Study-May
- INSIDERCFO Ye Xiaofeng sold $164,635 worth of American Depositary Shares (11,667 units at $14.11), decreasing direct ownership by 7% to 147,757 units (SEC Form 4) to satisfy withholding tax4 - Adlai Nortye Group Ltd. (0001944552) (Issuer)
- SECSEC Form 6-K filed by Adlai Nortye Ltd.6-K - Adlai Nortye Group Ltd. (0001944552) (Filer)
- SECSEC Form 6-K filed by Adlai Nortye Ltd.6-K - Adlai Nortye Ltd. (0001944552) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Adlai Nortye Ltd.SCHEDULE 13G/A - Adlai Nortye Ltd. (0001944552) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Adlai Nortye Ltd.SCHEDULE 13G/A - Adlai Nortye Ltd. (0001944552) (Subject)
- SECSEC Form 6-K filed by Adlai Nortye Ltd.6-K - Adlai Nortye Ltd. (0001944552) (Filer)
- PRAdlai Nortye Ltd. Reports Unaudited First Half 2026 Financial Results and Highlights Recent Operational ProgressEnrollment ongoing in both QD and QW arms of global Phase I trial of pan-RAS(ON) inhibitor AN9025 First regulatory approval obtained for Phase I trial of pan-RAS(ON) ADC AN4035 Two leading medical oncologists appointed to Scientific Advisory Board SINGAPORE and NORTH BRUNSWICK, N.J., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ:ANL) (the "Company" or "Adlai Nortye"), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced its business highlights and its first half financial results for the period ended June 30, 2026. "We continue to execute well across our pipeline, with initial clinical data on track fo
- INSIDERNew insider Birgerson Lars Erik claimed ownership of 166,668 units of American Depositary Shares (SEC Form 3)3 - Adlai Nortye Ltd. (0001944552) (Issuer)
- SECSEC Form 6-K filed by Adlai Nortye Ltd.6-K - Adlai Nortye Ltd. (0001944552) (Filer)
- PRAdlai Nortye Announces Clinical Trial Notification Submission and HREC Approval for the Phase I Clinical Trial of Pan-RAS(ON) Inhibitor ADC AN4035 in AustraliaFirst-in-class pan-RAS(ON) ADC is cleared for clinical development Designed to selectively deliver pan-RAS(ON) inhibition to tumors while minimizing systemic toxicity. IND submissions to U.S. FDA and China NMPA are in process SINGAPORE and NORTH BRUNSWICK, N.J., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ:ANL) ("Adlai Nortye" or the "Company"), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced that it has submitted a Clinical Trial Notification (CTN) to Australia's Therapeutic Goods Administration (TGA) and received approval from the Human Research Ethics Committee (HREC) to commence its phase I clinical tri
- SECSEC Form 424B7 filed by Adlai Nortye Ltd.424B7 - Adlai Nortye Ltd. (0001944552) (Filer)
ANL FAQ
6 questionsWhere does ANL stock trade?
Adlai Nortye Ltd. (ANL) is listed on NASDAQ.What sector and industry is ANL in?
Adlai Nortye Ltd. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Adlai Nortye Ltd. go public?
Adlai Nortye Ltd. (ANL) completed its IPO in 2023.What are analysts saying about ANL?
Adlai Nortye Ltd. has had 8 recent analyst actions on file. The most recent action was from Jefferies: Buy with a $3100.00 price target on 2026-09-10. Recent price targets range from $900.00 to $3200.00.What companies are similar to ANL?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare ANL side-by-side with any of them on Quantisnow.How can I track ANL on Quantisnow?
Quantisnow aggregates Adlai Nortye Ltd.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ANL to receive live email and push alerts on every new disclosure.